; and (ii) any updates to information previously published in accordance with subparagraph (A). . (2) Public listing of patent information (A) In general The Secretary of Health and Human Services shall include in the recommendations transmitted to Congress under section 744I(f) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–53(f) ) recommendations with respect to the collection and publication of patent information in the list described in section 351(o) of the Public Health Service Act ( 42 U.S.C. 262 ), as added by paragraph (1). (B) Development In developing recommendations under subparagraph (A), the Secretary of Health and Human Services may consult with the Federal Trade Commission, the Director of the United States Patent and Trademark Office, and the Federal Trade Commission, in addition to the entities listed in section 744I(f)(1) of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 379j–53(f)(1) ). (b) Rule of construction Nothing in this section, including the amendment made by this section, shall be construed to require or allow the Secretary of Health and Human Services to delay the review or approval of a biologic license application under section 351 of the Public Health Service Act ( 42 U.S.C. 262 ). 402. Antitrust exemption for health insurance issuers To negotiate wholesale acquisition prices of prescription drugs purchased from drug manufacturers (a) Exemption It shall not be a violation of the antitrust laws for one or more health insurance issuers or their designated agents to jointly negotiate wholesale acquisition prices of a prescription drug with a manufacturer of a prescription drug with regards to the reimbursement policies of the insurers of the manufacturer’s drugs so long as no single wholesale acquisition price is jointly determined between the insurance issuers or their designated agents. (b) Definitions For purposes of this section: (1) Antitrust laws The term antitrust laws has the meaning given it in subsection (a) of the 1st section of the Clayton Act ( 15